Morton J Cowan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2916493/publications.pdf

Version: 2024-02-01

76	4,823	126907	95266
papers	citations	33 h-index	68 g-index

84	84	84	4482
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Poor T-cell receptor Î² repertoire diversity early posttransplant for severe combined immunodeficiency predicts failure of immune reconstitution. Journal of Allergy and Clinical Immunology, 2022, 149, 1113-1119.	2.9	8
2	Quantitative brain MRI morphology in severe and attenuated forms of mucopolysaccharidosis type I. Molecular Genetics and Metabolism, 2022, 135, 122-132.	1.1	5
3	Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 196-202.	1.2	12
4	Granulocyte Transfusions in Patients with Chronic Granulomatous Disease Undergoing Hematopoietic Cell Transplantation or Gene Therapy. Journal of Clinical Immunology, 2022, 42, 1026-1035.	3.8	3
5	Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC. Blood, 2022, 140, 685-705.	1.4	26
6	Lentivector cryptic splicing mediates increase in CD34+ clones expressing truncated HMGA2 in human X-linked severe combined immunodeficiency. Nature Communications, 2022, 13, .	12.8	19
7	Unknown cytomegalovirus serostatus in primary immunodeficiency disorders: A new category of transplant recipients. Transplant Infectious Disease, 2021, 23, e13504.	1.7	2
8	Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers. Journal of Clinical Immunology, 2021, 41, 38-50.	3.8	36
9	The Relationship Between Busulfan Exposure and Achievement of Sustained Donor Myeloid Chimerism in Patients with Non-Malignant Disorders. Transplantation and Cellular Therapy, 2021, 27, 258.e1-258.e6.	1.2	3
10	Successful SCID gene therapy in infant with disseminated BCG. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 993-995.e1.	3.8	3
11	Expectations and experience: Parent and patient perspectives regarding treatment for Severe Combined Immunodeficiency (SCID). Clinical Immunology, 2021, 229, 108778.	3.2	0
12	JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived NaÃ¯ve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID). Blood, 2021, 138, 554-554.	1.4	5
13	Extended Follow-up After Hematopoietic Cell Transplantation for IÎºBÎ± Deficiency with Disseminated Mycobacterium avium Infection. Journal of Clinical Immunology, 2020, 40, 248-250.	3.8	1
14	Reduced Toxicity Conditioning for Nonmalignant Hematopoietic Cell Transplants. Biology of Blood and Marrow Transplantation, 2020, 26, 1646-1654.	2.0	9
15	Adenosine Deaminase (ADA)â€“Deficient Severe Combined Immune Deficiency (SCID) in the US Immunodeficiency Network (USIDNet) Registry. Journal of Clinical Immunology, 2020, 40, 1124-1131.	3.8	19
16	Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood, 2020, 135, 2094-2105.	1.4	87
17	Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Frontiers in Immunology, 2020, 11, 239.	4.8	57
18	Allograft and patient survival after sequential HSCT and kidney transplantation from the same donorâ€”A multicenter analysis. American Journal of Transplantation, 2019, 19, 475-487.	4.7	14

#	Article	IF	Citations
19	Quality of Life of Patients with Wiskott Aldrich Syndrome and X-Linked Thrombocytopenia: a Study of the Primary Immune Deficiency Consortium (PIDTC), Immune Deficiency Foundation, and the Wiskott-Aldrich Foundation. Journal of Clinical Immunology, 2019, 39, 786-794.	3.8	11
20	Newborn Screening for Severe Combined Immunodeficiency and T-cell Lymphopenia in California, 2010â€“2017. Pediatrics, 2019, 143, .	2.1	148
21	Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study. Journal of Allergy and Clinical Immunology, 2019, 143, 2238-2253.	2.9	60
22	Low Exposure Busulfan Conditioning to Achieve Sufficient Multilineage Chimerism in Patients with Severe Combined Immunodeficiency. Biology of Blood and Marrow Transplantation, 2019, 25, 1355-1362.	2.0	22
23	Supporting caregivers during hematopoietic cell transplantation for children with primary immunodeficiency disorders. Journal of Allergy and Clinical Immunology, 2019, 143, 2271-2278.	2.9	9
24	Psychosocial services for primary immunodeficiency disorder families during hematopoietic cell transplantation: A descriptive study. Palliative and Supportive Care, 2019, 17, 409-414.	1.0	2
25	The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). Journal of Allergy and Clinical Immunology, 2019, 143, 405-407.	2.9	64
26	Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. Journal of Allergy and Clinical Immunology, 2018, 141, 322-328.e10.	2.9	79
27	Donor lymphocyte infusion and methotrexate for immune recovery after Tâ€cell depleted haploidentical transplantation. American Journal of Hematology, 2018, 93, 169-178.	4.1	9
28	Advances and highlights in primary immunodeficiencies in 2017. Journal of Allergy and Clinical Immunology, 2018, 142, 1041-1051.	2.9	7
29	SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood, 2018, 132, 1737-1749.	1.4	128
30	Application of a radiosensitivity flow assay in a patient with DNA ligase 4 deficiency. Blood Advances, 2018, 2, 1828-1832.	5.2	13
31	B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. Blood, 2018, 131, 2967-2977.	1.4	37
32	Outcome of domino hematopoietic stem cell transplantation in human subjects: An international case series. Journal of Allergy and Clinical Immunology, 2018, 142, 1628-1631.e4.	2.9	1
33	Evaluation of Preâ€“Hematopoietic Cell Transplantation (HCT) Brain MRI and Neurologic Complications of Pediatric Patients Undergoing HCT for Hematologic Malignancies. Journal of Pediatric Oncology Nursing, 2017, 34, 65-73.	1.5	0
34	Transplacental maternal engraftment and posttransplantation graft-versus-host disease in children with severe combined immunodeficiency. Journal of Allergy and Clinical Immunology, 2017, 139, 628-633.e10.	2.9	30
35	Treatment of infants identified as having severe combined immunodeficiency by means of newborn screening. Journal of Allergy and Clinical Immunology, 2017, 139, 733-742.	2.9	73
36	Recommendations for Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogenic Hematopoietic Cell Transplantation: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biology of Blood and Marrow Transplantation, 2017, 23, 1229-1240.	2.0	44

#	Article	IF	Citations
37	Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report. Biology of Blood and Marrow Transplantation, 2017, 23, 1342-1349.	2.0	50
38	Genotype, Phenotype and T Cell Counts at One Year Predict Survival and Long Term Immune Reconstitution after Transplantation in Severe Combined Immune Deficiency (SCID)â€"The Primary Immune Deficiency Treatment Consortium (PIDTC). Biology of Blood and Marrow Transplantation, 2017, 23, S133-S134.	2.0	4
39	Reticular dysgenesis: international survey on clinical presentation, transplantation, and outcome. Blood, 2017, 129, 2928-2938.	1.4	31
40	Immune reconstitution and survival of 100 SCID patients postâ€"hematopoietic cell transplant: a PIDTC natural history study. Blood, 2017, 130, 2718-2727.	1.4	212
41	Long term outcomes of severe combined immunodeficiency: therapy implications. Expert Review of Clinical Immunology, 2017, 13, 1029-1040.	3.0	22
42	Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2017, 23, 1701-1713.	2.0	32
43	Opening Marrow Niches in Patients Undergoing Autologous Hematopoietic Stem Cell Gene Therapy. Hematology/Oncology Clinics of North America, 2017, 31, 809-822.	2.2	8
44	The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Biology of Blood and Marrow Transplantation, 2017, 23, 24-29.	2.0	33
45	Neurologic eventâ€"free survival demonstrates a benefit for SCID patients diagnosed by newborn screening. Blood Advances, 2017, 1, 1694-1698.	5.2	14
46	Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content. Frontiers in Immunology, 2017, 8, 798.	4.8	41
47	Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematology,the, 2016, 3, e526-e536.	4.6	197
48	Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B. New England Journal of Medicine, 2016, 375, 2165-2176.	27.0	104
49	Devouring the Hematopoietic Stem Cell: Setting the Table for Marrow Cell Transplantation. Molecular Therapy, 2016, 24, 1892-1894.	8.2	3
50	Primary Immune Deficiency Treatment Consortium (PIDTC) update. Journal of Allergy and Clinical Immunology, 2016, 138, 375-385.	2.9	33
51	Unrelated Hematopoietic Cell Transplantation in a Patient with Combined Immunodeficiency with Granulomatous Disease and Autoimmunity Secondary to RAG Deficiency. Journal of Clinical Immunology, 2016, 36, 725-732.	3.8	19
52	Severe, persistent, and fatal Tâ€cell immunodeficiency following therapy for infantile leukemia. Pediatric Blood and Cancer, 2016, 63, 2046-2049.	1.5	12
53	Radiation-sensitive severe combined immunodeficiency: The arguments for and against conditioning before hematopoietic cell transplantationâ€"what to do?. Journal of Allergy and Clinical Immunology, 2015, 136, 1178-1185.	2.9	63
54	Successful newborn screening for SCID in the Navajo Nation. Clinical Immunology, 2015, 158, 29-34.	3.2	48

#	Article	IF	Citations
55	Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment. Molecular Genetics and Metabolism, 2015, 116, 61-68.	1.1	59
56	Population Pharmacokinetics of Busulfan in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplant. Therapeutic Drug Monitoring, 2015, 37, 236-245.	2.0	67
57	Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. Journal of Clinical Investigation, 2015, 125, 4135-4148.	8.2	159
58	Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United States. JAMA - Journal of the American Medical Association, 2014, 312, 729.	7.4	586
59	Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: The Primary Immune Deficiency Treatment Consortium experience. Journal of Allergy and Clinical Immunology, 2014, 133, 1092-1098.	2.9	301
60	Primary Immune Deficiency Treatment Consortium (PIDTC) report. Journal of Allergy and Clinical Immunology, 2014, 133, 335-347.e11.	2.9	65
61	Transplantation Outcomes for Severe Combined Immunodeficiency, 2000â€“2009. New England Journal of Medicine, 2014, 371, 434-446.	27.0	594
62	Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment ofÂsevere combined immunodeficiency. Journal of Allergy and Clinical Immunology, 2014, 134, 935-943.e15.	2.9	82
63	Survey on retransplantation criteria for patients with severe combined immunodeficiency. Journal of Allergy and Clinical Immunology, 2014, 133, 597-599.	2.9	5
64	SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood, 2014, 123, 281-289.	1.4	150
65	The Natural History of Children with Severe Combined Immunodeficiency: Baseline Features of the First Fifty Patients of the Primary Immune Deficiency Treatment Consortium Prospective Study 6901. Journal of Clinical Immunology, 2013, 33, 1156-1164.	3.8	100
66	Effect of Weight and Maturation on Busulfan Clearance in Infants and Small Children Undergoing Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1608-1614.	2.0	69
67	Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood, 2011, 118, 1675-1684.	1.4	296
68	Hematopoietic Stem Cell Transplantation for Severe Combined Immunodeficiency Diseases. Biology of Blood and Marrow Transplantation, 2008, 14, 73-80.	2.0	22
69	Megadose CD34 + Cell Grafts Improve Recovery of T Cell Engraftment but not B Cell Immunity in Patients with Severe Combined Immunodeficiency Disease Undergoing Haplocompatible Nonmyeloablative Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 1125-1133.	2.0	47
70	Effects of B7.2â^'/â^' Mature Dendritic Cells on Tolerance Induction to Alloantigens in Fetal Mice Following In Utero Transplantation with Lineage Depleted Bone Marrow.. Blood, 2004, 104, 2134-2134.	1.4	0
71	A new gene involved in DNA double-strand break repair and V(D)J recombination is located on human chromosome 10p. Human Molecular Genetics, 2000, 9, 583-588.	2.9	85
72	Siblings' Perceptions of the Bone Marrow Transplantation Process. Journal of Psychosocial Oncology, 1997, 15, 81-105.	1.2	34

#	Article	IF	Citations
73	Maternal mosaicism for a novel interleukin-2 receptor gamma-chain mutation causing X-linked severe combined immunodeficiency in a Navajo kindred. Journal of Clinical Immunology, 1997, 17, 29-33.	3.8	26
74	Microgranulomatous aspergillosis after shoveling wood chips: Report of a fatal outcome in a patient with chronic granulomatous disease. American Journal of Industrial Medicine, 1992, 22, 411-418.	2.1	19
75	ASPERGILLUS PNEUMONIA IN CHRONIC GRANULOMATOUS DISEASE: RECURRENCE AND LONG-TERM OUTCOME. Acta Paediatrica, International Journal of Paediatrics, 1982, 71, 915-917.	1.5	15
76	Intermittent ataxia and immunodeficiency with multiple carboxylase deficiencies: A biotin-responsive disorder. Annals of Neurology, 1980, 8, 544-547.	5.3	55